Laura Elizabeth Lansdowne
Managing Editor
As managing editor, Laura works closely with the editorial director to create, inform and maintain the overall editorial strategy for Technology Networks. She plays an active part in the general oversight and training of the in-house editorial team, as well as working directly with commissioned writers to produce content across the publication’s communities. After obtaining a first-class honors degree in biology, Laura worked as a quality assurance technologist before joining the Wellcome Sanger Institute and undertaking an additional qualification in clinical chemistry. In 2015, she left to pursue pharmaceutical and editorial based roles, before joining Technology Networks in 2017.
Latest Content
Article
Reconnecting at ELRIG Drug Discovery 2021
Technology Networks is delighted to be reporting – in person – from The European Laboratory Research & Innovation Group (ELRIG)'s Drug Discovery 2021 meeting. In this article, we explore the key themes discussed in the meeting's opening address.
Article
Uncovering Key Interactions Between Cancer-Driving Proteins
Research conducted as part of the Cancer Cell Map Initiative (CCMI), has revealed interactions between cancer-driving proteins, that were unknown, until now. Findings were published in three separate papers in Science.
Industry Insight
Early Detection of Brain Tumors and Beyond
The ability to detect a tumor earlier, when it is smaller, reduces the impact of surgery and treatment, improving the prognosis for many patients. Dxcover has developed a new spectroscopic liquid biopsy approach that is able to identify brain tumors as small as 0.2 cm3 from a blood sample in as little as fifteen minutes.
Industry Insight
Large-Scale Bioproduction of Adherent Cells To Support Advanced Therapy Workflows
In recent years, a number of new cell and gene therapies have been developed to treat a variety of indications, including cancer and inherited retinal dystrophies. While these therapies have proven to be beneficial to patients, their scalability and manufacturability are two enduring challenges. Technology Networks spoke to Tara St.Amand, PhD, MBA, director of business technology, bioprocess at Corning to learn more about the key challenges faced when scaling up the manufacturing of cell products.
Infographic
Spatial Biology
Download this infographic to discover how spatial biology can elucidate biological activity in relation to environment, is utilized in neuroscience and cancer research, and can be explored using various technologies.
Industry Insight
Simulator Technology Can Predict Optimal Vaccine Dosing
Certara is developing biosimulation and tech-enabled approaches to help scientists answer key questions at various stages of the development pipeline, serving to inform and accelerate the path to regulatory approval. One such approach, the company’s Vaccine Simulator™, can be leveraged across different therapeutic areas to determine optimal vaccine dosing and dosing regimens for different patient cohorts.
News
Treating Hearing Loss: The Hunt for Drugs That Promote Hair Cell Regeneration
A research team from Nanjing University has used cochlear organoids to identify drugs that can promote the regeneration of hair cells. The study, published in Stem Cell Reports, also identifies a signaling pathway as a potential target for hearing restoration.
News
High-Intensity Focused Ultrasound: A Novel Non-Invasive Cancer Treatment
A research team has examined the use of high-intensity focused ultrasound as a non-invasive cancer treatment that works by targeting acoustic waves to destroy cancer cells. The study was published in Bulletin of Mathematical Biology.
Podcast
Opinionated Science Episode 34: Genetics of Endometriosis, the Birthing Brain and Cancer Vaccines
In this episode, the Technology Networks team reviews world-leading research into the mechanisms behind endometriosis, a condition that affects up to 10% of women of reproductive age, but often takes a decade to diagnose. There's also a peek into mom's brain during birth and a new cancer vaccine that harnesses similar technology used to create the Oxford–AstraZeneva COVID-19 vaccine.
News
Nine Existing Drugs Reduce SARS-CoV-2 Viral Load in Cell-Based Study
A new study by researchers at the University of Manchester suggests that existing FDA-approved drugs may be suitable for repurposing as prophylactics, or for use in combination with vaccine therapy, to ward off COVID-19.
Advertisement